Compare LSPD & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSPD | NNNN |
|---|---|---|
| Founded | 2005 | 2021 |
| Country | Canada | Germany |
| Employees | N/A | 27 |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2020 | N/A |
| Metric | LSPD | NNNN |
|---|---|---|
| Price | $9.33 | $28.60 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $13.33 | N/A |
| AVG Volume (30 Days) | ★ 807.6K | 11.2K |
| Earning Date | 05-21-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.43 | N/A |
| Revenue Next Year | $10.94 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.37 | $6.26 |
| 52 Week High | $14.34 | $55.65 |
| Indicator | LSPD | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 64.30 |
| Support Level | $8.45 | $26.48 |
| Resistance Level | $9.71 | $30.21 |
| Average True Range (ATR) | 0.32 | 1.60 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 36.94 | 91.77 |
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).